Bristol-Myers Squibb Company (BMY) Stock Price: $56.48+0.91 (+1.64%)
The total return cagr for Bristol-Myers Squibb Company (BMY) stock is 21.06% over the past 12 months. The 3 year average growth rate is 0.06% and the 5 year cagr is 1.10%. Total return includes dividends reinvested.
The closing share price for Bristol-Myers Squibb Company (BMY) stock was $56.48 for Tuesday, June 9, 2026, up +1.64% from the previous day.
BMY Price Chart
BMY Key Metrics
See All MetricsBMY Earnings Preview
Next Earnings Date
Jul 30, 2026
51 days away
EPS Estimate
1.61
Revenue Est.
$11.70B
Last Quarter Results
EPS
$1.58
vs Estimate
$1.42
Revenue
$11.49B
vs Estimate
$10.93B
BMY Analyst Ratings
Consensus Rating
Based on 25 analysts
Average Price Target
$63.08
+11.7% upside
Low
$40.00
Current
$56.48
High
$75.00
BMY Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $1.38 | N/A | 6 |
| Q2 2027 | N/A | $1.55 | N/A | 6 |
| Q3 2027 | N/A | $1.53 | N/A | 6 |
| Q4 2027 | N/A | $1.55 | N/A | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $6.14 | N/A | 17 |
| FY 2028 | N/A | $5.39 | N/A | 9 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | N/A | $10.91B | N/A | 6 |
| Q2 2027 | N/A | $11.43B | N/A | 6 |
| Q3 2027 | N/A | $11.60B | N/A | 6 |
| Q4 2027 | N/A | $12.05B | N/A | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | N/A | $46.30B | N/A | 17 |
| FY 2028 | N/A | $40.98B | N/A | 9 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
BMY Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1BMY | $115.34B | $56.48 | +1.64% | +21.06% | +1.10% | +0.95% |
BMY Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner